FDA Approves Novel Drug Orzeyful for Narcolepsy Type 1

The U.S. Food and Drug Administration (FDA) has approved Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. This marks the first drug to directly activate the brain receptor that the body's own orexin would normally stimulate, addressing the underlying biology of the disease rather than just masking symptoms.